Scarica l'app Stockscreener
10.18
0.10%
0.010
Translational Development Acquisition Corp Borsa (TDAC) Ultime notizie
WOLVERINE ASSET MANAGEMENT LLC Acquires Significant Stake in Translational Development Acquisition Corp - GuruFocus
Secretome Therapeutics Appoints New Chief Medical Officer - Dallas Innovates
Secretome Therapeutics Appoints Dr. Marshelle Smith Warren as Chief Medical Officer - BioSpace
Artis BioSolutions Emerges from Stealth, Announces Acquisition of Landmark Bio - BioSpace
Translational Development Acquisition Corp. (TDAC) reports earnings - Quartz
Pioneering Innovative Drug Development at Cambridge Crossing Facility - Bristol Myers Squibb
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - BioSpace
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Major SPAC Update: TDACU Splits Units into Separate Shares & Warrants Trading - Stock Titan
Trident Acquisitions stock hits 52-week high of $10.08 By Investing.com - Investing.com Australia
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development - GlobeNewswire
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com UK
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Trident Acquisitions stock hits 52-week high at $10.04 - Investing.com Australia
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - Stock Titan
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - Stock Titan
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
Rapid effects of valproic acid on the fetal brain transcriptome: implications for brain development and autism - Nature
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel - GlobeNewswire
Deal Watch: Dealmakers Brace for Impact of Presidential Election - Law.com
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities - GlobeNewswire
Ipsen and Foreseen Biotechnology announce exclusive global - GlobeNewswire
Research and development center Cambridge, Massachusetts - Bristol Myers Squibb
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire
Novartis Acquires Mariana Oncology To Advance Radiopharmaceuticals For Cancer Treatment - Pharmaceutical Online
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering and Biotechnology News
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
ENSEM Appoints Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer - citybiz
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering and Biotechnology News
SSI Strategy and NDA Group Combine to Form Best-in-Class Global Life Sciences Consultancy - Business Wire
FirstEnergy issues earnings report - 69News WFMZ-TV
Spatial Genomics and Transcriptomics Market Size Report, 2032 - Global Market Insights Inc.
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure - News-Medical.Net
NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
IPO Pricings Archives - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature
Translatome and transcriptome co-profiling reveals a role of TPRXs in human zygotic genome activation - Science | AAAS
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Why Kymab Agreed to be Acquired by Sanofi - Timmerman Report
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
VeriSIM Life Announces Acquisition of Molomics Biotech - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
BioSpace Movers & Shakers, Jan. 21 - BioSpace
Third Rock Ventures Promotes David Kaufman, M.D., Ph.D., to Partner - citybiz
Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing - BioSpace
Research and Development grant cheat sheet - The University of Sydney
Crown Bioscience Unveils New Identity - Business Wire
A red blood cell disease meets a company with a plasma protein heritage - Nature
Key considerations on the development of biodegradable biomaterials for clinical translation of medical devices: With cartilage repair products as an example - ScienceDirect.com
Trident Acquisitions Corp. Files 10K/A - Barchart.com
CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings - Business Wire
BioSpace Movers & Shakers, March 19 - BioSpace
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. - Business Wire
BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More - BioSpace
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio - Business Wire
(PDF) Cultural, textual and linguistic aspects of legal translation: A model of text analysis for training legal translators - ResearchGate
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development - The Lancet
The Vertex Method’s Success Story - Genetic Engineering and Biotechnology News
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire
Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy - Business Wire
1.16%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):